#HYPEHitsAllTimeHigh 📊 U.S. Market Update: Tech Correction Deepens as Biotech Defies the Trend 🩺💡

Market Overview (As of June 3, 2026)
The broader U.S. stock market experienced a notable shift today. Mega-cap technology giants faced a broad sell-off and entered a correction phase, heavily weighed down by cooling AI sentiment and capital expenditure concerns. Conversely, the biotech sector showed massive resilience, charting a strong inverse rally, while energy stocks gained solid ground tracking rising crude prices.
Here is a deep-dive technical breakdown of today’s key movers:
📉 Tech & AI Giants Under Pressure
NVIDIA ($NVDA) | 🛑 Down 3.62% ($214.75)
Technical Snapshot: Broke below its 21-day moving average, erasing 7.5% from Tuesday’s intraday highs.
Outlook: Indicators point to an active correction phase. Keep a close eye on the $200–$210 key support zone; a breach here could open the door for a deeper retracement.
Microsoft ($MSFT) | 🛑 Down 3.17% ($427.34)
Technical Snapshot: Broke below the critical 200-day moving average, putting its medium-to-long-term uptrend under technical pressure.
Catalyst: After-hours earnings reported solid top-line revenue growth, but flagged slowing forward momentum. Heightened market anxiety regarding AI-related Capex suggests continued near-term volatility.
IBM ($IBM) | 🛑 Down 7.20% ($305.63)
Technical Snapshot: A steep decline accompanied by a 73% surge in trading volume—a classic institutional distribution warning signal.
Outlook: Short-term momentum remains heavily bearish. Watch the $300 psychological support line; if failed, a retest of $290 is likely.
Amazon ($AMZN) | 📉 Down 2.53% ($250.02)
Technical Snapshot: Currently navigating a secondary correction after snapping its short-term trendline. Long-term trend support sits close by at $246.
Outlook: Consolidating at a critical crossroads. If the $240–$250 pocket stabilizes, a reclaiming of $250 could ignite a fresh rally.
📈 Pockets of Outperformance: Big Tech & Bio
Meta Platforms ($META) | 🚀 Up 4.24% ($622.98)
Technical Snapshot: Defied the mega-cap tech sell-off, surging through its short-term descending trendline.
Outlook: Major resistance looms near the long-term trendline at $640. If META can sustain its base above $620 and clear $640, expect further extension. Otherwise, look for a retest of $600 support.
Eli Lilly ($LLY) | 🚀 Up 1.40% ($1,078.78)
Technical Snapshot: Successfully broke above its high "handle" downtrend, offering an early structural buy trigger.
Outlook: Technical indicators are in a strong bullish alignment. Momentum points toward an immediate target of $1,100.
Neurocrine Biosciences ($NBIX) | 🚀 Up 6.60% ($165.11)
Technical Snapshot: Reclaimed and closed firmly above its $160.18 cup-and-handle breakout point.
Outlook: A classic institutional accumulation pattern. Holding above $165 sets the stage for a continuation toward $170.
TG Therapeutics ($TGTX) | 🔥 Up 9.50% ($40.11)
Technical Snapshot: Bounced aggressively off its 50-day moving average.
Catalyst: Driven by positive clinical data on its new multiple sclerosis pipeline. Immediate strength is evident; look for a definitive breakout past the $40–$42 resistance ceiling.
🔍 Macro Takeaway
We are likely entering a high-level consolidation phase for the broader indexes. Rotation is the name of the game right now. As tech takes a breather to digest its massive gains, capital is visibly fleeing into defensive biotech setups and inflation-hedged energy assets.
What to watch next: Corporate earnings guidance, evolving macroeconomic/geopolitical risks, and upcoming inflation data will be the ultimate arbiters of whether this tech pullback is a healthy buying opportunity or a deeper regime shift.
Disclaimer: This post is for informational and educational purposes only and does not constitute financial advice.
#ETHPlunges5PercentBelow1800